Health IT Analytics November 8, 2022
Artificial intelligence supported a clinical trial that found that low-dose ketamine could be a therapeutic target for a rare genetic disease.
Artificial intelligence (AI) supported a clinical trial focused on assessing treatment methods for a rare genetic disease known as activity-dependent neuroprotective protein (ADNP) syndrome.
ADNP syndrome is a rare condition due to a mutation of the ADNP gene. The disease affects the brain and various body functions, including hearing and vision, according to the National Institutes of Health.
Researchers from the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham used an AI tool known as mediKanren that flagged useful clinical evidence, helping them identify low-dose ketamine as a potential therapeutic target for ADNP syndrome.
...